Table 2. Primary and Secondary Outcomesa.
| Variable | Intervention Group (n = 209) | Control Group (n = 202) | Unadjusted Effect Estimate | Adjusted Effect Estimate | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wk 0 | Wk 12 | Change | Wk 0 | Wk 12 | Change | Absolute Difference | P Value | Absolute Difference | P Value | |
| Primary outcomes | ||||||||||
| Medication adherence,b mean (SD) | 6.0 (1.8) | 6.3 (1.6) | 0.4 (1.5) | 5.7 (1.8) | 5.7 (1.8) | −0.01 (1.5) | 0.4 (0.1 to 0.7) | .01 | 0.5 (0.2 to 0.7) | .001 |
| Systolic BP, mm Hg, mean (SD) | 151.4 (9.0) | 140.8 (15.7) | −10.6 (16.0) | 151.3 (9.4) | 141.2 (17.3) | −10.1 (15.4) | −0.5 (−3.7 to 2.7) | .78 | −0.1 (−3.2 to 3.1) | .97 |
| Secondary outcome | ||||||||||
| Controlled BP,c No. (%) | 0 | 67 (35.8) | 35.8 | 0 | 69 (37.9) | 37.9 | OR, 0.9 (95% CI, 0.6 to 1.4) | .68 | OR, 0.8 (95% CI, 0.5 to 1.3) | .34 |
Abbreviations: BP, blood pressure; OR, odds ratio.
a
The results presented herein reflect the primary analyses of the trial outcomes, which were conducted after multiple imputation. The adjusted models controlled for: sex, race/ethnicity, body mass index, physical activity, education, cigarette use, patient activation, and baseline adherence.
b
Measured by 8-item Morisky Medication Adherence Scale.
c
Defined as BP <140/90 mm Hg.